Report Overview

Indian Leukaemia market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Acute lymphoblastic leukemia (ALL) is the single most common pediatric malignancy accounting for 1/4th of all childhood cancer and 3/4th of all newly diagnosed leukemia. The incidence of childhood ALL is approximately 3- 4 cases per 100,000 children under the age of 15 years. Overall, males experience a slightly higher leukemia risk than females. Increased prevalence of ALL among adolescents in Eastern India. In India, every year nearly 25,000 children are Source: diagnosed with this cancer. Acute myeloid leukemia (AML) an annual incidence in India varying from 0.9 to 1.5 per 100,000 children. One of the commonest single gene disorders in India. It has been estimated that there would be 30 to 40 million carriers of beta-thalassemia in the country. Every year 7000-10,000 children with Thalassemia Major are born in India. Factors such as the large number of treatment options available for the treatment of CML and high incidence rate of CML are significantly driving the growth of leukaemia market.



Market Drivers

The market size drivers for the growth of Leukaemia cancer diagnostics are expected to propel by rise in the number of cigarette smokers, & growing R&D investments and reimbursement policies. Factors such as rising incidence of Leukaemia cancer and growing research activities for developing novel treatments coupled with increasing government funding for the cancer treatment research are driving the leukaemia cancer treatment market.